BioSpace News Archive

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases, announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020, 10:00 a.m. ET.

DiscernDx, today announced the expansion of the company’s precision medicine solutions with the acquisition of Luminist Labs, a privately-held novel diagnostic platform company for the early detection and diagnosis of liver disease.

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity Catalent to hire 300 additional personnel to meet operational readiness and 24x7 manufacturing schedules

Accellix, Inc. is launching its Next Generation Integrated Accellix Instrument and Consumables to further automate, simplify and improve reproducibility during the intricate process of QC for cell therapy manufacturing. Accellix entered the cell therapy market in 2017, automating the complete flow cytometry workflow, from sample preparation to analysis, which is considered the golden standard in QC.

Bimini Health Tech announced today it received FDA 510(k) clearance for its novel fat harvesting system, Dermapose Access (K200168).

VolitionRx Limited today announced results from its first proof of concept study conducted by Texas A&M University.

Partnership with global telemedicine leader MediOrbis creates a social distancing compliant, complete care Dario solution

Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing. Remdesivir is not yet licensed or approved anywhere globa

Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer and other life-threatening diseases, today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DS

Companies to utilize proprietary platforms to discover, develop, and manufacture potential therapeutic antibodies to combat ongoing COVID-19 pandemic